Nexalin Technology, Inc. develops non-invasive neurostimulation products based on Deep Intracranial Frequency Stimulation, or DIFS™, for brain-health and mental-health indications. Company news commonly covers peer-reviewed clinical publications, neuroimaging and biomarker data, and research programs addressing insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.
Updates also describe the HALO™ Clarity device, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA engagement, and capital-market communications tied to its Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.